-
The 2021 edition of the basic medicine catalog management method is released!
Time of Update: 2021-12-07
The types and quantities of adjustments should be determined based on the following factors: (1) China's basic medical and health service needs and basic medical security level changes; (2) China's disease spectrum changes; (3) Adverse drug reaction monitoring and evaluation; (4) Drug use monitoring And clinical comprehensive evaluation; (5) Evidence-based medicine and pharmacoeconomic evaluation of marketed drugs; (6) Other conditions specified by the National Essential Medicines Working Committee .
-
Treadwell Therapeutics released a report at the 2021 SITC (Society for Cancer Immunotherapy) annual meeting, introducing the clinical application of the first HPK1 inhibitor CFI-402411 of its kind.
Time of Update: 2021-12-07
Hematopoietic progenitor kinase 1 (HPK1) has a negative regulatory effect on immune cell activation, and CFI-402411 is the first oral inhibitor of its kind against HPK1 .
-
Opportunities in these fields have come after the collection
Time of Update: 2021-12-07
The trend of low-level competition will be terminated, which is also in line with the global development trend of the pharmaceutical industry-gradually concentrated, and small and medium-sized enterprises without innovative capabilities will be eliminated .
-
2021 annual performance forecast: Chutian Technology, Dongfulong and other stocks are expected to increase
Time of Update: 2021-12-07
As of November 17, 2021, within 6 months, a total of one institution, China Securities Construction Investment, has made a prediction on Tailin Bio's 2021 annual performance; forecast 2021 net profit is 0.
-
Domestic reflux esophagitis drugs "first imitation battle" adds new members
Time of Update: 2021-12-07
It is understood that the launch of voronola fumarate green tablets provides a new treatment option for patients with reflux esophagitis .
In terms of generic drugs, on November 15th, Kelun Pharmaceutical reported Takeda Original Research's voronola fumarate green tablets for generic 4 types and was accepted (acceptance number CYHS2102022, CYHS2102023) .
-
Changes in the chairman of two well-known pharmaceutical companies
Time of Update: 2021-12-07
In addition, under the influence of national policies, the pharmaceutical distribution industry has become more competitive in the industry, leading companies have obvious advantages, and the rise of new business forms such as Internet hospitals is also an important factor affecting its development .
-
From selling cosmetics, coffee to lottery tickets, chain pharmacies continue to try new formats!
Time of Update: 2021-12-07
According to the data, Yixintang is a large-scale retail chain enterprise focusing on pharmaceutical business.
-
Deck Pharmaceuticals announced the positive preclinical data of two drugs during the SITC annual meeting on November 12
Time of Update: 2021-12-07
At the same time, it is further analyzed by quantitative system pharmacological model Supported the dose selection strategy for the drug-Preclinical data of ERK1/2 inhibitor ATG-017 combination therapy supports future clinical developmentShanghai and Hong Kong November 15, 2021/PRNewswire/ - Deqi Pharmaceutical Co.
-
The API industry welcomes favorable policies, or accelerates the innovation and upgrading of the pharmaceutical equipment industry
Time of Update: 2021-12-07
With the advancement of centralized procurement policies, consistency evaluation, and drug-related approvals, as well as the impact of factors such as global order transfers, the scale of China's API
-
"Paste health preservation" has become the theme of winter tonic, and the equipment behind it should not be underestimated
Time of Update: 2021-12-07
In recent years, in the face of increasing patient demand and the rapid development of modern technology, the application and innovation of ointment are in the ascendant, the process standards and requirements are continuously improved, the production is more and more exquisite, the processing requirements are more and more refined, and the equipment is also more and more refined.
-
Osaikang Pharmaceutical's third-generation EGFR-TKI new drug listing application accepted
Time of Update: 2021-12-07
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is an earlier developed targeted drug for the treatment of NSCLC and has undergone three generations of product evolution .
In addition, Osaikang Pharmaceutical is also developing Class 1 new drugs for the treatment of NSCLC with Exon14 mutations and third-generation EGFR inhibitor resistance .
-
The official release of an important signal, the third round of national mining has come?
Time of Update: 2021-12-07
The "Notice" mentioned that in order to reduce repetitive operations and improve work efficiency, relevant companies have completed information maintenance in the Henan, Jinxi, Jiangxi, Hubei, Chongqing, Guizhou, Yunnan, Guining, Qingxiang and Hebei orthopedic trauma medical consumables procurement project led by Henan Province.
-
New medicine for cystic fibrosis!
Time of Update: 2021-12-07
Vertex Pharmaceuticals recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting the approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor) and ivacaftor combination drug regimen label expansion for treatment All CF patients aged 6 to 11 years with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene .
-
Accelerate the substitution of original research drugs, local pharmaceutical companies are constantly making efforts
Time of Update: 2021-12-07
At present, with the continuous efforts of local pharmaceutical companies, domestic high-end generic drugs are accelerating the replacement of the original research drug market position .
-
Are biopharmaceutical companies "out of favor"?
Time of Update: 2021-12-07
Since the second half of this year, there has been frequent news of Hillhouse reducing its holdings in the pharmaceutical outsourcing industry: On August 25, Hillhouse withdrew from Tigermed’s top ten
-
Pien Tze Huang Apixaban tablets received drug registration certificate to prevent venous thromboembolism
Time of Update: 2021-12-07
On November 15, Pien Tze Huang issued an announcement stating that the company's Apixaban tablets received the "Drug Registration Certificate" approved and issued by NMPA . Apixaban is a new oral ant
-
The scale of the Chinese medicine market continues to expand, and high-quality development becomes the top priority of pharmaceutical companies
Time of Update: 2021-12-07
According to this trend, the industry predicts that the market size of China's traditional Chinese medicine industry will maintain a compound annual growth rate of about 14% in the next few years.
-
The epilepsy drug market may break the 6 billion mark, and pharmaceutical companies compete for the first imitation of sodium valproate oral solution
Time of Update: 2021-12-07
With the production of Sichuan Baojiantang Sodium Valproate Oral Solution, the field of antiepileptic drugs may usher in new competitors .
In the field of sodium valproate injection, companies applying for consistency evaluation include Fu'an Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang, and Sichuan Creed Pharmaceuticals .
-
The market is fully liberalized, and a large number of traditional Chinese medicine companies are stepping up their deployment in the field of traditional Chinese medicine formula particles
Time of Update: 2021-12-07
Currently, Shenwei Pharmaceutical has invested more than 1 billion yuan in research on the preparation process and quality standards, pharmacodynamics and clinical application of Chinese medicine formula granules, and has achieved significant results .
-
The number of entrants in the Chinese medicine formula granule market is increasing, and the market war is about to start
Time of Update: 2021-12-07
The project is expected to produce 1,049 tons of decoction pieces and formula granules of various types of Chinese medicine in the first year of production, with an output value of 238 million yuan.
